메뉴 건너뛰기




Volumn 163, Issue , 2015, Pages 143-158

Immunotherapy for malignant gliomas

Author keywords

CTLA 4; Glioblastoma; Glioma; Immunotherapy; PD 1; PD L1; Vaccine

Indexed keywords

BASILIXIMAB; BEVACIZUMAB; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 96; IPILIMUMAB; NIVOLUMAB; PEPTIDE VACCINE; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; RINDOPEPIMUT; SL 701; SURVIVIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VITESPEN; WT1 PROTEIN; CANCER VACCINE;

EID: 84916604843     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-319-12048-5_9     Document Type: Article
Times cited : (13)

References (62)
  • 1
    • 4143141823 scopus 로고    scopus 로고
    • The immunobiology of cancer immunosurveillance and immunoediting
    • pii: S1074761304002092
    • Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148. doi:10.1016/j.immuni.2004.07.017, pii: S1074761304002092
    • (2004) Immunity , vol.21 , pp. 137-148
    • Dunn, G.P.1    Old, L.J.2    Schreiber, R.D.3
  • 2
    • 79953151458 scopus 로고    scopus 로고
    • Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion
    • pii:331/6024/1565
    • Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570. doi:10.1126/science.1203486, pii: 331/6024/1565
    • (2011) Science , vol.331 , pp. 1565-1570
    • Schreiber, R.D.1    Old, L.J.2    Smyth, M.J.3
  • 3
    • 34347323902 scopus 로고    scopus 로고
    • Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis
    • pii: S0140-6736(07)61050-2
    • Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370: 59–67. doi:10.1016/S0140-6736(07)61050-2, pii: S0140-6736(07)61050-2
    • (2007) Lancet , vol.370 , pp. 59-67
    • Grulich, A.E.1    Van Leeuwen, M.T.2    Falster, M.O.3    Vajdic, C.M.4
  • 4
    • 84977155391 scopus 로고    scopus 로고
    • Tumor immunology and cancer immunotherapy: Summary of the 2013 SITC primer
    • pii: 2051-1426-2-14
    • Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P (2014) Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer 2:14. doi:10.1186/2051-1426-2-14, pii: 2051-1426-2-14
    • (2014) J Immunother Cancer , vol.2 , pp. 14
    • Raval, R.R.1    Sharabi, A.B.2    Walker, A.J.3    Drake, C.G.4    Sharma, P.5
  • 5
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792. doi:10.1056/NEJM200103153441101
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 6
    • 77953413843 scopus 로고    scopus 로고
    • Chimeric T cells for adoptive immunotherapy of cancer: Using what have we learned to plan for the future
    • Peinert S, Kershaw MH, Prince HM (2009) Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future. Immunotherapy 1:905–912. doi: 10.2217/imt.09.69
    • (2009) Immunotherapy , vol.1 , pp. 905-912
    • Peinert, S.1    Kershaw, M.H.2    Prince, H.M.3
  • 7
    • 84255197842 scopus 로고    scopus 로고
    • Cancer immunotherapy comes of age
    • pii: nature10673
    • Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480–489. doi:10.1038/nature10673, pii: nature10673
    • (2011) Nature , vol.480 , pp. 480-489
    • Mellman, I.1    Coukos, G.2    Dranoff, G.3
  • 8
    • 0025195542 scopus 로고
    • T-cell clones that react against autologous human tumors
    • Mukherji B, Chakraborty NG, Sivanandham M (1990) T-cell clones that react against autologous human tumors. Immunol Rev 116:33–62
    • (1990) Immunol Rev , vol.116 , pp. 33-62
    • Mukherji, B.1    Chakraborty, N.G.2    Sivanandham, M.3
  • 9
    • 0028932731 scopus 로고
    • The CTL’s kiss of death
    • pii: 0092-8674(95)90365-8
    • Berke G (1995) The CTL’s kiss of death. Cell 81(1):9–12. doi:10.1016/0092-8674(95)90365-8, pii: 0092-8674(95)90365-8
    • (1995) Cell , vol.81 , Issue.1 , pp. 9-12
    • Berke, G.1
  • 10
    • 0025753704 scopus 로고
    • The IL-2 mediated amplification of cellular cytotoxicity
    • Grimm EA, Owen-Schaub L (1991) The IL-2 mediated amplification of cellular cytotoxicity. J Cell Biochem 45:335–339. doi:10.1002/jcb.240450405
    • (1991) J Cell Biochem , vol.45 , pp. 335-339
    • Grimm, E.A.1    Owen-Schaub, L.2
  • 11
    • 16644401873 scopus 로고    scopus 로고
    • Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    • pii: 23/1/133
    • McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133–141. doi:10.1200/JCO.2005.03.206, pii: 23/1/133
    • (2005) J Clin Oncol , vol.23 , pp. 133-141
    • McDermott, D.F.1    Regan, M.M.2    Clark, J.I.3
  • 12
    • 0027524697 scopus 로고
    • Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma
    • Sparano JA, Fisher RI, Sunderland M et al (1993) Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11:1969–1977
    • (1993) J Clin Oncol , vol.11 , pp. 1969-1977
    • Sparano, J.A.1    Fisher, R.I.2    Sunderland, M.3
  • 13
    • 84897934799 scopus 로고    scopus 로고
    • TLR agonists for cancer immunotherapy: Tipping the balance between the immune stimulatory and inhibitory effects
    • Lu H (2014) TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects. Front Immunol 5:83. doi:10.3389/fimmu.2014.00083
    • (2014) Front Immunol , vol.5 , pp. 83
    • Lu, H.1
  • 14
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • pii: nrc3239
    • Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. doi:10.1038/nrc3239, pii: nrc3239
    • (2012) Nat Rev Cancer , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 15
    • 77749279776 scopus 로고    scopus 로고
    • PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
    • pii: 0915174107
    • Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275–4280. doi:10.1073/pnas.0915174107, pii: 0915174107
    • (2010) Proc Natl Acad Sci USA , vol.107 , pp. 4275-4280
    • Curran, M.A.1    Montalvo, W.2    Yagita, H.3    Allison, J.P.4
  • 16
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. doi:10.1056/NEJMoa1001294
    • (2010) N Engl J Med , vol.363 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3
  • 17
    • 2542430341 scopus 로고    scopus 로고
    • The three Es of cancer immunoediting
    • Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360. doi:10.1146/annurev.immunol.22.012703.104803
    • (2004) Annu Rev Immunol , vol.22 , pp. 329-360
    • Dunn, G.P.1    Old, L.J.2    Schreiber, R.D.3
  • 18
    • 13544272944 scopus 로고    scopus 로고
    • Differential activation of astrocytes by innate and adaptive immune stimuli
    • Carpentier PA, Begolka WS, Olson JK, Elhofy A, Karpus WJ, Miller SD (2005) Differential activation of astrocytes by innate and adaptive immune stimuli. Glia 49:360–374. doi:10.1002/glia.20117
    • (2005) Glia , vol.49 , pp. 360-374
    • Carpentier, P.A.1    Begolka, W.S.2    Olson, J.K.3    Elhofy, A.4    Karpus, W.J.5    Miller, S.D.6
  • 19
    • 0035153212 scopus 로고    scopus 로고
    • Immune function of astrocytes
    • pii: glia.1107
    • Dong Y, Benveniste EN (2001) Immune function of astrocytes. Glia 36(2):180–190. doi:10.1002/glia.1107, pii: glia.1107
    • (2001) Glia , vol.36 , Issue.2 , pp. 180-190
    • Dong, Y.1    Benveniste, E.N.2
  • 20
    • 0037942601 scopus 로고    scopus 로고
    • The blood-brain barrier and its role in immune privilege in the central nervous system
    • Pachter JS, de Vries HE, Fabry Z (2003) The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 62:593–604
    • (2003) J Neuropathol Exp Neurol , vol.62 , pp. 593-604
    • Pachter, J.S.1    De Vries, H.E.2    Fabry, Z.3
  • 22
    • 63849335831 scopus 로고    scopus 로고
    • Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation
    • pii: 10.3171/2008.7.JNS08475
    • Parney IF, Waldron JS, Parsa AT (2009) Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg 110:572–582. doi:10.3171/2008.7.JNS08475, pii: 10.3171/2008.7.JNS08475
    • (2009) J Neurosurg , vol.110 , pp. 572-582
    • Parney, I.F.1    Waldron, J.S.2    Parsa, A.T.3
  • 23
    • 77956868654 scopus 로고    scopus 로고
    • Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance
    • Hatanpaa KJ, Burma S, Zhao D, Habib AA (2010) Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 12:675–684
    • (2010) Neoplasia , vol.12 , pp. 675-684
    • Hatanpaa, K.J.1    Burma, S.2    Zhao, D.3    Habib, A.A.4
  • 24
    • 67349137902 scopus 로고    scopus 로고
    • The EGFRvIII variant in glioblastoma multiforme
    • pii: S0967-5868(09)00046-0
    • Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16:748–754. doi:10.1016/j.jocn.2008.12.005, pii: S0967-5868(09)00046-0
    • (2009) J Clin Neurosci , vol.16 , pp. 748-754
    • Gan, H.K.1    Kaye, A.H.2    Luwor, R.B.3
  • 25
    • 67650688162 scopus 로고    scopus 로고
    • The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
    • Heimberger AB, Sampson JH (2009) The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 9:1087–1098. doi:10.1517/14712590903124346
    • (2009) Expert Opin Biol Ther , vol.9 , pp. 1087-1098
    • Heimberger, A.B.1    Sampson, J.H.2
  • 26
    • 78149254368 scopus 로고    scopus 로고
    • Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    • pii: JCO.2010.28.6963
    • Sampson JH, Heimberger AB, Archer GE et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729. doi:10.1200/JCO.2010.28.6963, pii: JCO.2010.28.6963
    • (2010) J Clin Oncol , vol.28 , pp. 4722-4729
    • Sampson, J.H.1    Heimberger, A.B.2    Archer, G.E.3
  • 27
    • 43249090418 scopus 로고    scopus 로고
    • Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
    • Izumoto S, Tsuboi A, Oka Y et al (2008) Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:963–971. doi:10.3171/JNS/2008/108/5/0963
    • (2008) J Neurosurg , vol.108 , pp. 963-971
    • Izumoto, S.1    Tsuboi, A.2    Oka, Y.3
  • 29
    • 84905817445 scopus 로고    scopus 로고
    • Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas
    • pii: JCO.2013.54.0526
    • Pollack IF, Jakacki RI, Butterfield LH et al (2014) Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. doi:10.1200/JCO.2013.54.0526, pii: JCO.2013.54.0526
    • (2014) J Clin Oncol
    • Pollack, I.F.1    Jakacki, R.I.2    Butterfield, L.H.3
  • 30
    • 84860209098 scopus 로고    scopus 로고
    • Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
    • pii: aws042
    • Dutoit V, Herold-Mende C, Hilf N et al (2012) Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 135:1042–1054. doi:10.1093/brain/aws042, pii: aws042
    • (2012) Brain , vol.135 , pp. 1042-1054
    • Dutoit, V.1    Herold-Mende, C.2    Hilf, N.3
  • 31
    • 84872498982 scopus 로고    scopus 로고
    • Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
    • Phuphanich S, Wheeler CJ, Rudnick JD et al (2013) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 62:125–135. doi:10.1007/s00262-012-1319-0
    • (2013) Cancer Immunol Immunother , vol.62 , pp. 125-135
    • Phuphanich, S.1    Wheeler, C.J.2    Rudnick, J.D.3
  • 32
    • 84873989551 scopus 로고    scopus 로고
    • Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients
    • Prins RM, Wang X, Soto H et al (2013) Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother 36:152–157. doi:10.1097/CJI.0b013e3182811ae4
    • (2013) J Immunother , vol.36 , pp. 152-157
    • Prins, R.M.1    Wang, X.2    Soto, H.3
  • 33
    • 23044479028 scopus 로고    scopus 로고
    • Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
    • pii: 11/15/5515
    • Liau LM, Prins RM, Kiertscher SM et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515–5525. doi:10.1158/1078-0432.CCR-05-0464, pii: 11/15/5515
    • (2005) Clin Cancer Res , vol.11 , pp. 5515-5525
    • Liau, L.M.1    Prins, R.M.2    Kiertscher, S.M.3
  • 34
    • 48649096955 scopus 로고    scopus 로고
    • Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
    • pii: 68/14/5955
    • Wheeler CJ, Black KL, Liu G et al. (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:5955–5964. doi:10.1158/0008-5472.CAN-07-5973, pii: 68/14/5955
    • (2008) Cancer Res , vol.68 , pp. 5955-5964
    • Wheeler, C.J.1    Black, K.L.2    Liu, G.3
  • 35
    • 66149117488 scopus 로고    scopus 로고
    • Treating human cancers with heat shock protein-peptide complexes: The road ahead
    • Srivastava PK, Callahan MK, Mauri MM (2009) Treating human cancers with heat shock protein-peptide complexes: the road ahead. Expert Opin Biol Ther 9:179–186. doi:10.1517/14712590802633918
    • (2009) Expert Opin Biol Ther , vol.9 , pp. 179-186
    • Srivastava, P.K.1    Callahan, M.K.2    Mauri, M.M.3
  • 36
    • 1942501656 scopus 로고    scopus 로고
    • Essential role of CD91 in re-presentation of gp96-chaperoned peptides
    • pii: 0308180101
    • Binder RJ, Srivastava PK (2004) Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci USA 101:6128–6133. doi:10.1073/pnas.0308180101, pii: 0308180101
    • (2004) Proc Natl Acad Sci USA , vol.101 , pp. 6128-6133
    • Binder, R.J.1    Srivastava, P.K.2
  • 37
    • 84871951211 scopus 로고    scopus 로고
    • Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein
    • pii: 1078-0432.CCR-11-3358
    • Crane CA, Han SJ, Ahn B et al (2013) Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res 19:205–214. doi:10.1158/1078-0432.CCR-11-3358, pii: 1078-0432.CCR-11-3358
    • (2013) Clin Cancer Res , vol.19 , pp. 205-214
    • Crane, C.A.1    Han, S.J.2    Ahn, B.3
  • 38
    • 84893073441 scopus 로고    scopus 로고
    • Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: A phase II, single-arm trial
    • pii: not203
    • Bloch O, Crane CA, Fuks Y et al (2014) Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol 16:274–279. doi:10.1093/neuonc/not203, pii: not203
    • (2014) Neuro Oncol , vol.16 , pp. 274-279
    • Bloch, O.1    Crane, C.A.2    Fuks, Y.3
  • 40
    • 0015461544 scopus 로고
    • Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor
    • Brooks WH, Netsky MG, Normansell DE, Horwitz DA (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 136:1631–1647
    • (1972) J Exp Med , vol.136 , pp. 1631-1647
    • Brooks, W.H.1    Netsky, M.G.2    Normansell, D.E.3    Horwitz, D.A.4
  • 41
    • 0021332509 scopus 로고
    • Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors
    • Elliott LH, Brooks WH, Roszman TL (1984) Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J Immunol 132:1208–1215
    • (1984) J Immunol , vol.132 , pp. 1208-1215
    • Elliott, L.H.1    Brooks, W.H.2    Roszman, T.L.3
  • 42
    • 77956345180 scopus 로고    scopus 로고
    • Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy
    • pii: S0165-5728(10)00211-0
    • Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos G, Kostoula A, Voulgari P, Polyzoidis K, Kyritsis AP (2010) Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J Neuroimmunol 226: 36–42. doi:10.1016/j.jneuroim.2010.05.027, pii: S0165-5728(10)00211-0
    • (2010) J Neuroimmunol , vol.226 , pp. 36-42
    • Gousias, K.1    Markou, M.2    Arzoglou, V.3    Voulgaris, S.4    Vartholomatos, G.5    Kostoula, A.6    Voulgari, P.7    Polyzoidis, K.8    Kyritsis, A.P.9
  • 43
    • 84860507700 scopus 로고    scopus 로고
    • T-regulatory cells: Key players in tumor immune escape and angiogenesis
    • pii: 72/9/2162
    • Facciabene A, Motz GT, Coukos G (2012) T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 72:2162–2171. doi:10.1158/0008-5472.CAN-11-3687, pii: 72/9/2162
    • (2012) Cancer Res , vol.72 , pp. 2162-2171
    • Facciabene, A.1    Motz, G.T.2    Coukos, G.3
  • 44
    • 33645502885 scopus 로고    scopus 로고
    • Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma
    • pii: 66/6/3294
    • Fecci PE, Mitchell DA, Whitesides JF et al (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66:3294–3302. doi:10.1158/0008-5472.CAN-05-3773, pii: 66/6/3294
    • (2006) Cancer Res , vol.66 , pp. 3294-3302
    • Fecci, P.E.1    Mitchell, D.A.2    Whitesides, J.F.3
  • 46
    • 33846215511 scopus 로고    scopus 로고
    • Profiling of CD4+, CD8+, and CD4+ CD25+ CD45RO+ FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers
    • pii: 12/24/7306
    • Learn CA, Fecci PE, Schmittling RJ et al. (2006) Profiling of CD4+, CD8+, and CD4+ CD25+ CD45RO+ FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res 12:7306–7315. doi:10.1158/1078-0432.CCR-06-1727, pii: 12/24/7306
    • (2006) Clin Cancer Res , vol.12 , pp. 7306-7315
    • Learn, C.A.1    Fecci, P.E.2    Schmittling, R.J.3
  • 47
    • 84860358785 scopus 로고    scopus 로고
    • Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: Implications for immunotherapy
    • pii: nos014
    • Crane CA, Ahn BJ, Han SJ, Parsa AT (2012) Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol 14:584–595. doi:10.1093/neuonc/nos014, pii: nos014
    • (2012) Neuro Oncol , vol.14 , pp. 584-595
    • Crane, C.A.1    Ahn, B.J.2    Han, S.J.3    Parsa, A.T.4
  • 48
    • 33748492962 scopus 로고    scopus 로고
    • Prolongation of survival following depletion of CD4+ CD25+ regulatory T cells in mice with experimental brain tumors
    • El Andaloussi A, Han Y, Lesniak MS (2006) Prolongation of survival following depletion of CD4+ CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 105:430–437. doi:10.3171/jns.2006.105.3.430
    • (2006) J Neurosurg , vol.105 , pp. 430-437
    • El Andaloussi, A.1    Han, Y.2    Lesniak, M.S.3
  • 49
    • 84857547272 scopus 로고    scopus 로고
    • A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma
    • pii: PONE-D-11-20574
    • Sampson JH, Schmittling RJ, Archer GE et al (2012) A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One 7:e31046. doi:10.1371/journal.pone.0031046, pii: PONE-D-11-20574
    • (2012) Plos One , pp. 7
    • Sampson, J.H.1    Schmittling, R.J.2    Archer, G.E.3
  • 50
    • 84859258334 scopus 로고    scopus 로고
    • Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients
    • pii: PONE-D-11-22564
    • Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, Li G, Liau LM, Prins RM (2012) Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One 7:e32614. doi:10.1371/journal.pone.0032614, pii: PONE-D-11-22564
    • (2012) Plos One , pp. 7
    • Fong, B.1    Jin, R.2    Wang, X.3    Safaee, M.4    Lisiero, D.N.5    Yang, I.6    Li, G.7    Liau, L.M.8    Prins, R.M.9
  • 51
    • 84886948036 scopus 로고    scopus 로고
    • B7 family checkpoint regulators in immune regulation and disease
    • pii: S1471-4906(13)00110-5
    • Ceeraz S, Nowak EC, Noelle RJ (2013) B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 34:556–563. doi:10.1016/j.it.2013.07.003, pii: S1471-4906(13)00110-5
    • (2013) Trends Immunol , vol.34 , pp. 556-563
    • Ceeraz, S.1    Nowak, E.C.2    Noelle, R.J.3
  • 52
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • pii: NEJMoa1003466
    • Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. doi:10.1056/NEJMoa1003466, pii: NEJMoa1003466
    • (2010) N Engl J Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    O’Day, S.J.2    McDermott, D.F.3
  • 53
    • 18544380239 scopus 로고    scopus 로고
    • Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
    • pii: nm730
    • Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800. doi:10.1038/nm730, pii: nm730
    • (2002) Nat Med , vol.8 , pp. 793-800
    • Dong, H.1    Strome, S.E.2    Salomao, D.R.3
  • 54
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465. doi:10.1056/NEJMoa1200694
    • (2012) N Engl J Med , vol.366 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3
  • 55
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. doi:10.1056/NEJMoa1200690
    • (2012) N Engl J Med , vol.366 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3
  • 56
    • 33846118474 scopus 로고    scopus 로고
    • Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
    • pii: nm1517
    • Parsa AT, Waldron JS, Panner A et al (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13:84–88. doi: 10.1038/nm1517, pii: nm1517
    • (2007) Nat Med , vol.13 , pp. 84-88
    • Parsa, A.T.1    Waldron, J.S.2    Panner, A.3
  • 58
    • 84879484111 scopus 로고    scopus 로고
    • Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages
    • pii: 1078-0432.CCR-12-3314
    • Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT (2013) Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 19:3165–3175. doi:10.1158/1078-0432.CCR-12-3314, pii: 1078-0432.CCR-12-3314
    • (2013) Clin Cancer Res , vol.19 , pp. 3165-3175
    • Bloch, O.1    Crane, C.A.2    Kaur, R.3    Safaee, M.4    Rutkowski, M.J.5    Parsa, A.T.6
  • 62
    • 79952956629 scopus 로고    scopus 로고
    • Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients with glioblastoma (GBM)
    • (suppl; abstract number 2014)
    • Lai R, Recht LD, Reardon DA, Paleologos N, Groves MD, Rosenfeld MR, Meech S, Davis TA, Pavlov D, Sampson JH (2010) Interim data for ACT III: phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients with glioblastoma (GBM). J Clin Oncol 28:15s (suppl; abstract number 2014)
    • (2010) J Clin Oncol , vol.28 , pp. 15s
    • Lai, R.1    Recht, L.D.2    Reardon, D.A.3    Paleologos, N.4    Groves, M.D.5    Rosenfeld, M.R.6    Meech, S.7    Davis, T.A.8    Pavlov, D.9    Sampson, J.H.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.